MIM
REGN icon

Macroview Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Macroview Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$2.1K – 434
2024
Q3 		$2.1K Hold
2
– – ﹤0.01% 470
2024
Q2 		$2.1K Hold
2
– – ﹤0.01% 484
2024
Q1 		$1.93K Sell
2
-7
-78% -$6.66K ﹤0.01% 543
2023
Q4 		$7.91K Hold
9
– – 0.01% 284
2023
Q3 		$7.41K Buy
+9
New +$7.07K 0.01% 321
2019
Q4 		– Sell
-13
Closed -$4K – 331
2019
Q3 		$4K Buy
+13
New +$3.85K 0.01% 201
2019
Q2 		– Sell
-8
Closed -$3K – 353
2019
Q1 		$3K Buy
+8
New +$3.29K 0.01% 267

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macroview Investment Management's REGN Position: Q4 2024 in Review

Macroview Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 2 shares — an estimated $2.1K sold.

Macroview Investment Management first reported a position in REGN in Q1 2019 and held it in 7 quarters. The position peaked at $7.91K in Q4 2023. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Macroview Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Macroview Investment Management sold 2 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $2.1K.
  • Macroview Investment Management first reported a position in Regeneron Pharmaceuticals in Q1 2019 and held it in 7 quarters.
  • Macroview Investment Management's Regeneron Pharmaceuticals position peaked at $7.91K in Q4 2023.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Macroview Investment Management's 13F filing for Q4 2024, filed 31 Jan 2025.